SGLT2 Inhibitors: Frequently Asked QuestionsTo date, management of diabetes has focussed on enhanced insulin secretion or sensitivity to the hormone. An emerging strategy enhances renal elimination of glucose from the body by blocking the SGLT2 transporter.
Only the content of this FAQ page has been validated by the FMOQ
Respective product monographs as per July 2015
While there are differences within the class, SGLT2 inhibitors therapies are uniformly approved as second-line therapies; as add-on to metformin when metformin alone fails to provide adequate glycemic control.
Efficacy and impact on weight: